1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways
The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
1. A compound of formula (IA):
or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof; wherein
R a is hydrogen or acyl;
R 1 represents hydrogen, —(CH 2 ) 2 CONH 2 , —(CH 2 ) 2 COOH, —CH 2 COOH, —(CH 2 ) 3 NH(C═NH)NH 2 , —(CH 2 ) 4 NH 2 , —CH 2 CONH 2 , —CH(CH 3 )—CH 2 —CH 3 , —CH 2 -aryl, or —CH 2 -heteroaryl; wherein the aryl and heteroaryl are unsubstituted; or R a and R 1 , together with the atoms to which they are attached form pyrrolidine ring optionally substituted with oxo group; and
R 2 represents hydrogen, —CH 2 —OH, —(CH 2 ) 2 CONH 2 , —(CH 2 ) 2 COOH, —CH 2 -aryl, or —CH 2 -heteroaryl; wherein the said aryl and heteroaryl are unsubstituted.
2. The compound of claim 1 , wherein R 1 represents hydrogen, —(CH 2 ) 2 CONH 2 , —(CH 2 ) 2 COOH, —CH 2 COOH, —(CH 2 ) 3 NHC(═NH)NH 2 , —(CH 2 ) 4 NH 2 , —CH 2 -aryl, or —CH 2 -heteroaryl.
3. The compound of claim 1 , wherein R 1 represents hydrogen, —CH 2 —COOH, —(CH 2 ) 2 CONH 2 , —(CH 2 ) 2 COOH, —(CH 2 ) 3 NH(C═NH)NH 2 , —(CH 2 ) 4 NH 2 , —CH 2 -phenyl, —CH 2 -indolyl or —CH 2 -imidazolyl.
4. The compound of claim 1 , wherein R 1 represents —(CH 2 ) 2 CONH 2 or —(CH 2 ) 2 COOH.
5. The compound of claim 1 , wherein R a is hydrogen.
6. The compound of claim 1 , wherein R 2 represents hydrogen, —CH 2 —OH, —(CH 2 ) 2 CONH 2 , —(CH 2 ) 2 COOH, —CH 2 -phenyl, or —CH 2 -imidazolyl.
7. The compound of claim 1 , wherein R 2 represents hydrogen, —(CH 2 ) 2 CONH 2 , or —(CH 2 ) 2 COOH.
8. The compound of claim 1 , wherein R 2 represents hydrogen.
9. The compound of claim 1 , wherein
R a is hydrogen; and R 1 represents hydrogen, —(CH 2 ) 2 CONH 2 , —(CH 2 ) 2 COOH, —CH 2 COOH, —(CH 2 ) 3 NHC(═NH)NH 2 , —(CH 2 ) 4 NH 2 , —CH 2 -aryl, or —CH 2 -heteroaryl; wherein the aryl and heteroaryl are unsubstituted; and
R 2 represents hydrogen, —CH 2 —OH, —(CH 2 ) 2 CONH 2 , —(CH 2 ) 2 COOH, —CH 2 -aryl, or —CH 2 -heteroaryl; wherein the said aryl and heteroaryl are unsubstituted.
10. The compound of claim 1 , wherein,
R a is hydrogen; and R 1 represents hydrogen, —CH 2 —COOH, —(CH 2 ) 2 CONH 2 , —(CH 2 ) 2 COOH, —(CH 2 ) 3 NHC(═NH)NH 2 , —(CH 2 ) 4 NH 2 , —CH 2 -phenyl, —CH 2 -indolyl or —CH 2 -imidazolyl;
R 2 represents hydrogen, —CH 2 —OH —(CH 2 ) 2 CONH 2 , —(CH 2 ) 2 COOH or —CH 2 -phenyl.
11. A compound selected from:
Compound
Structure
1
2
4
6
16
17
18
19
20
21
32
33
34
35
53
or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof.
12. A pharmaceutical composition comprising a compound of formula (IA) according to claim 1 , and a pharmaceutically acceptable carrier.
13. A method of modulating macrophage phagocytic activity towards a cancer cell or tumor cell in an individual comprising administering to the said individual an effective amount of a compound of formula (IA) according to claim 1 , wherein the cancer cell or tumor cell is a B-cell lymphoma.
14. The method of claim 13 , wherein the B-cell lymphoma is selected from Hodgkin's Disease, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphocytic lymphoma, and primary CNS lymphoma.
15. A method for treating or delaying progression of diseases or disorders mediated by CD47 in an individual, the method comprising administering to the said individual an effective amount of a compound of formula (IA) according to claim 1 , wherein the disease or disorder is a B-cell lymphoma.
16. The method of claim 15 , wherein the B-cell lymphoma is Hodgkin's Disease, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphocytic lymphoma, and primary CNS lymphoma.